Lenalidomid Aristo (Lenalidomide)

Lenalidomide binds to the cereblon protein, a component of the CRL4 E3 ubiquitin ligase complex. This binding triggers ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, leading to anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that suppress malignant plasma cells and dysplastic myeloid clones.

The specific dose of Lenalidomid Aristo is determined by the prescribing physician based on the patient’s clinical condition, disease stage, renal function, and concomitant therapies. Dosage regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Lenalidomide is classified as potentially teratogenic and is contraindicated in pregnancy. Women of childbearing potential must use effective contraception during treatment and for a defined period after discontinuation. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended while on therapy.

To order Lenalidomid Aristo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify institutional credentials, then provide pricing, availability, shipping details, and any necessary import documentation.

Lenalidomid Aristo belongs to the class of immunomodulatory imide drugs (IMiDs) and offers a distinct mechanism of action compared with proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens to improve response rates and progression‑free survival, especially in patients with relapsed or refractory disease.

Lenalidomid Aristo should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

Lenalidomid Aristo is taken orally, usually once daily, with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water. Patients should follow the dosing schedule provided by their healthcare professional and attend regular monitoring appointments.

Serious risks include venous thromboembolism, severe neutropenia that can predispose to infections, and the possible development of secondary primary malignancies. Patients should be monitored closely for signs of blood clots, infections, or unexpected changes in blood counts, and any concerning symptoms should be reported promptly.

Lenalidomid Aristo should not be used by individuals with known hypersensitivity to lenalidomide or any of its excipients. It is also contraindicated in pregnant women, women who are not using effective contraception, and patients with uncontrolled severe infections or significant organ dysfunction without appropriate medical oversight.